GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.
GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...
Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...
Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...
Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...
Nov. 12, 2024 — Researchers have identified a potential biomarker of Parkinson's disease progression. According to the new study, patients with a slow progression of ... Oct. 8, 2024 ...
News Medical on MSN1d
New biomarker could help predict Parkinson’s disease progressionA team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.
MedPage Today on MSN17h
Gabapentinoids Tied to Hip Fractures in Older AdultsRisks were high for people with chronic kidney disease or significant frailty. Odds of hip fracture remained high after ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback